Published in Am J Med Genet C Semin Med Genet on January 17, 2012
Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis (2014) 0.99
Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. PLoS One (2014) 0.85
Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up. Neurol Sci (2014) 0.79
Therapeutic advances in the management of Pompe disease and other metabolic myopathies. Ther Adv Neurol Disord (2013) 0.78
Targeted approaches to induce immune tolerance for Pompe disease therapy. Mol Ther Methods Clin Dev (2016) 0.77
Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy. Genet Med (2016) 0.75
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med (2011) 2.08
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med (2012) 2.05
Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med (2009) 1.99
Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab (2012) 1.79
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics (2011) 1.50
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med (2012) 1.31
Peripheral expression of self-MHC-II influences the reactivity and self-tolerance of mature CD4(+) T cells: evidence from a lymphopenic T cell model. Immunity (2002) 1.22
Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases. J Allergy Clin Immunol (2012) 1.15
Atypical immunologic response in a patient with CRIM-negative Pompe disease. Mol Genet Metab (2011) 1.14
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One (2013) 1.14
Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design. Am J Transplant (2004) 0.95
Therapies for inborn errors of metabolism: what has the orphan drug act delivered? Pediatrics (2010) 0.94
Clinical pharmacology as a cornerstone of orphan drug development. Nat Rev Drug Discov (2011) 0.94
Accelerating orphan drug development. Nat Rev Drug Discov (2010) 0.91
Regulatory T cells in γ irradiation-induced immune suppression. PLoS One (2012) 0.91
Scientific considerations for generic synthetic salmon calcitonin nasal spray products. AAPS J (2010) 0.89
Letter to the Editors: Concerning "CRIM-negative Pompe disease patients with satisfactory clinical outcomes on enzyme replacement therapy" by Al Khallaf et al. J Inherit Metab Dis (2013) 0.89
CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med (2015) 0.89
Skin allograft rejection. Curr Protoc Immunol (2009) 0.83
Embryonic stem cells cultured in serum-free medium acquire bovine apolipoprotein B-100 from feeder cell layers and serum replacement medium. Stem Cells (2007) 0.80
A novel function of RNAs arising from the long terminal repeat of human endogenous retrovirus 9 in cell cycle arrest. J Virol (2012) 0.79
Signaling through MHC in transgenic mice generates a population of memory phenotype cytolytic cells that lack TCR. Blood (2003) 0.77
Apolipoprotein B binding domains: evidence that they are cell-penetrating peptides that efficiently deliver antigenic peptide for cross-presentation of cytotoxic T cells. J Immunol (2011) 0.76
Defining new surrogate markers for CKD progression. Pediatr Nephrol (2014) 0.76
Langerhans cell dogma: another round of rejections. J Invest Dermatol (2008) 0.75
CD4+ T-cell responses to self-peptide--MHC. Trends Immunol (2003) 0.75
CORRIGENDUM: CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med (2015) 0.75
Microbial Risk in Pharmaceutical Manufacturing and ICH Q9. PDA J Pharm Sci Technol (2013) 0.75
A convenient method for positive selection of retroviral producing cells generating vectors devoid of selectable markers. J Virol Methods (2004) 0.75
An overview of cytokines and cytokine antagonists as therapeutic agents. Ann N Y Acad Sci (2009) 0.75